Trial Profile
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2022
Price :
$35
*
At a glance
- Drugs Alglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Therapeutic Use
- Acronyms ADVANCE
- Sponsors Sanofi Genzyme
- 01 Mar 2022 Results assessing Cardiac responses in paediatric Pompe disease patient cohort published in the Cardiology in the Young
- 26 Oct 2015 Status changed from completed to discontinued, according to ClinicalTrials.gov record.
- 09 Apr 2015 New trial record